Expression of CD73 on leukemic blasts increases during follow-up – a promising candidate marker for minimal residual disease detection in pediatric B-cell precursor acute lymphoblastic leukemia

Łukasz Słota; Łukasz Sędek; Jan Kulis; Bartosz Perkowski; Iwona Malinowska; Joanna Zawitkowska; Bernarda Kazanowska; Katarzyna Derwich; Maciej Niedźwiecki; Agnieszka Mizia-Malarz; Katarzyna Muszyńska-Rosłan; Andrzej Kołtan; Grażyna Karolczyk; Katarzyna Machnik; Tomasz Urasiński; Monika Lejman; Wanda Badowska; Wojciech Młynarski; Jerzy Kowalczyk; Tomasz Szczepański

doi:10.5114/ceji.2022.114530

eISSN: 1644-4124
ISSN: 1426-3912

Central European Journal of Immunology

Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures

Editorial System

Submit your Manuscript

1/2022
vol. 47

Send email

Copy url:

abstract:

Clinical immunology

Expression of CD73 on leukemic blasts increases during follow-up – a promising candidate marker for minimal residual disease detection in pediatric B-cell precursor acute lymphoblastic leukemia

Łukasz Słota

¹

,

Łukasz Sędek

²

,

Jan Kulis

¹

,

Bartosz Perkowski

¹

,

Iwona Malinowska

³

,

Joanna Zawitkowska

⁴

,

Bernarda Kazanowska

⁵

,

Katarzyna Derwich

⁶

,

Maciej Niedźwiecki

⁷

,

Agnieszka Mizia-Malarz

⁸

,

Katarzyna Muszyńska-Rosłan

⁹

,

Andrzej Kołtan

¹⁰

,

Grażyna Karolczyk

¹¹

,

Katarzyna Machnik

¹²

,

Tomasz Urasiński

¹³

,

Monika Lejman

¹⁴

,

Wanda Badowska

¹⁵

,

Wojciech Młynarski

¹⁶

,

Jerzy Kowalczyk

⁴

,

Tomasz Szczepański

¹

Department of Pediatric Hematology and Oncology, Medical University of Silesia, Katowice, Poland

Department of Microbiology and Immunology, Medical University of Silesia, Katowice, Poland

Department of Pediatrics, Hematology and Oncology, Medical University of Warsaw, Poland

Department of Pediatric, Hematology, Oncology and Transplantology, Medical University of Lublin, Poland

Department of Pediatric Transplantology, Oncology, Hematology, Medical University of Wrocław, Poland

Department of Pediatric Oncology, Hematology and Transplantology, Medical University of Poznań, Poland

Department of Pediatrics, Hematology, Oncology and Endocrinology, Medical University of Gdańsk, Poland

Department of Pediatric Oncology, Hematology and Chemotherapy, Medical University of Silesia, Katowice, Poland

Department of Pediatric Oncology, Hematology, Medical University of Białystok, Poland

10.

Department of Pediatrics, Hematology and Oncology, Collegium Medicum of Bydgoszcz, Poland

11.

Department of Pediatric Oncology and Hematology, Children’s Hospital, Kielce, Poland

12.

Department of Pediatric Hematology and Oncology, Center of Pediatrics and Oncology, Chorzów, Poland

13.

Department of Pediatrics, Hematology and Oncology, Medical University of Szczecin, Poland

14.

Laboratory of Genetic Diagnostics, Medical University of Lublin, Poland

15.

Department of Hematology and Oncology, Children State Hospital, Olsztyn, Poland

16.

Department of Pediatrics, Oncology and Hematology, Medical University of Łódź, Poland

Cent Eur J Immunol 2022; 47 (1): 84-91

DOI: https://doi.org/10.5114/ceji.2022.114530

Online publish date: 2022/03/17

View full text Get citation

EndNote

Papers, Reference Manager, RefWorks, Zotero

AMA

Słota Ł, Sędek Ł, Kulis J, et al. Expression of CD73 on leukemic blasts increases during follow-up – a promising candidate marker for minimal residual disease detection in pediatric B-cell precursor acute lymphoblastic leukemia. Central European Journal of Immunology. 2022;47(1):84-91. doi:10.5114/ceji.2022.114530.

APA

Słota, Ł., Sędek, Ł., Kulis, J., Perkowski, B., Malinowska, I.,  & Zawitkowska, J. et al. (2022). Expression of CD73 on leukemic blasts increases during follow-up – a promising candidate marker for minimal residual disease detection in pediatric B-cell precursor acute lymphoblastic leukemia. Central European Journal of Immunology, 47(1), 84-91. https://doi.org/10.5114/ceji.2022.114530

Chicago

Słota, Łukasz, Łukasz Sędek, Jan Kulis, Bartosz Perkowski, Iwona Malinowska, Joanna Zawitkowska,  and Bernarda Kazanowska et al. 2022. "Expression of CD73 on leukemic blasts increases during follow-up – a promising candidate marker for minimal residual disease detection in pediatric B-cell precursor acute lymphoblastic leukemia". Central European Journal of Immunology 47 (1): 84-91. doi:10.5114/ceji.2022.114530.

Harvard

Słota, Ł., Sędek, Ł., Kulis, J., Perkowski, B., Malinowska, I., Zawitkowska, J., Kazanowska, B., Derwich, K., Niedźwiecki, M., Mizia-Malarz, A., Muszyńska-Rosłan, K., Kołtan, A., Karolczyk, G., Machnik, K., Urasiński, T., Lejman, M., Badowska, W., Młynarski, W., Kowalczyk, J.,  and Szczepański, T. (2022). Expression of CD73 on leukemic blasts increases during follow-up – a promising candidate marker for minimal residual disease detection in pediatric B-cell precursor acute lymphoblastic leukemia. Central European Journal of Immunology, 47(1), pp.84-91. https://doi.org/10.5114/ceji.2022.114530

MLA

Słota, Łukasz et al. "Expression of CD73 on leukemic blasts increases during follow-up – a promising candidate marker for minimal residual disease detection in pediatric B-cell precursor acute lymphoblastic leukemia." Central European Journal of Immunology, vol. 47, no. 1, 2022, pp. 84-91. doi:10.5114/ceji.2022.114530.

Vancouver

Słota Ł, Sędek Ł, Kulis J, Perkowski B, Malinowska I, Zawitkowska J et al. Expression of CD73 on leukemic blasts increases during follow-up – a promising candidate marker for minimal residual disease detection in pediatric B-cell precursor acute lymphoblastic leukemia. Central European Journal of Immunology. 2022;47(1):84-91. doi:10.5114/ceji.2022.114530.

PlumX metrics:

Flow cytometry (FCM) is a precise and well-established tool to assess the minimal residual disease (MRD) level in childhood acute lymphoblastic leukemia (ALL). It is crucial to distinguish leukemic cells from their normal counterparts; thus new markers should be evaluated, to increase the accuracy of the analysis.

The expression of CD73 on blast cells was measured and compared at the day of diagnosis and at days 15 and 33 of treatment. To determine antigen expression levels, a normalized scale based on median fluorescence intensity (nMFI) was used. The study group consisted of 188 patients from the Polish Pediatric Leukemia and Lymphoma Study Group.

From 177 patients with positive MRD at day 15 of treatment, in 147 (83.1%) cases an increase of CD73 expression was observed (mean increase of +17 nMFI units). In addition, an increase of CD73 expression was noted in 26 of 31 (83.9%) patients at day 33 of treatment. In turn, a decrease of CD73 expression was observed only in 13/177 (7.3%) and 1/31 (3.2%) cases at days 15 and 33 of treatment, respectively. In 17 (9.6%) patients no change in expression of CD73 between diagnosis and day 15 of treatment was observed.

In the great majority of cases the expression of CD73 is not only stable but increases during the early stages of treatment, which makes it a very useful marker to be used for MRD monitoring in childhood B-cell precursor (BCP)-ALL patients.

keywords:

Expression of CD73 on leukemic blasts increases during follow-up – a promising candidate marker for minimal residual disease detection in pediatric B-cell precursor acute lymphoblastic leukemia

minimal residual disease, acute lymphoblastic leukemia, flow cytometry